Medable’s Intelligent Automation Capabilities Reduce Clinical Trial Technology Deployment Timelines

Medable Inc., the leading technology provider for modern clinical trials, announces new intelligent automation technology applied across its clinical trials platform to cut standard trial build timelines by at least half. Early application of the technology in electronic clinical outcomes assessment (eCOA) deployments – a major delay to study startup industry-wide – is groundbreaking. By automating laborious, manual tasks such as testing, Medable saves substantial time and removes eCOA from the critical path to trial go-live.

AiThority Interview Insights: AiThority Interview with Ramsey Masri, Chief Executive Officer at Ceres Imaging

Medable’s New Intelligent Automation Capabilities Cut Clinical Trial Technology Deployment Timelines by 50% #clinicaltrials #ai #clinicalresearch #studystartup #biosciences #healthcare #drugdevelopment

Medable’s new AI and automation capabilities catapult the company to the forefront of automating clinical trial operations and align with the industry’s perennial need to launch studies faster. Now, sponsors can eliminate common gridlocks caused by conversion, configuration, validation, and quality engineering. Top-10 global pharmaceutical companies are already benefiting from Medable’s novel technology, shaving weeks off build times.

As part of a broader roadmap incorporating AI and intelligent automation, Medable’s updated eCOA capabilities include an auto-configuration tool that produces standard configurations, such as schedules of assessments, anchor dates, and patient flags, in minutes. Medable’s auto-validate tool also eliminates weeks of tedious testing to automatically deliver a downloadable Configuration Validation Report (CVR) that validates the quality of study builds.

“We are reimagining the way clinical trials are deployed by eliminating many of the biggest process bottlenecks,” said Michelle Longmire, CEO and co-founder of Medable. “Starting with eCOA, we are accelerating clinical trials while helping to improve data quality – ultimately enabling our vision of a one-day study start-up to help deliver effective treatments and c**** to patients faster. In 2024, expect to see more innovative technologies and new ways of delivering streamlined, patient-centric trials from Medable.”

Read More about AiThority Interview: AiThority Interview with Jim Kaskade, Chief Executive Officer at Conversica

Medable, which ranked in the top 8% of software companies on the 2023 Inc. 5000, has deployed its software-as-a-service platform in more than 300 decentralized and hybrid clinical trials in 60 countries, serving more than one million patients and research participants globally. Customers have achieved impressive results – including 200 percent faster enrollment and 50 percent cost reductions. A Tufts Center for the Study of Drug Development study shows that, on average, decentralized trials can achieve net financial benefits from five to 13 times for Phase II and Phase III trials, equating to roughly $10 million ROI and $39 million ROI respectively.

AiThority Interview Insights : AiThority Interview with Itamar Kandel, Chief Executive Officer at Vista.ai

 [To share your insights with us, please write to sghosh@martechseries.com]